JP2012139223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012139223A5 JP2012139223A5 JP2012028435A JP2012028435A JP2012139223A5 JP 2012139223 A5 JP2012139223 A5 JP 2012139223A5 JP 2012028435 A JP2012028435 A JP 2012028435A JP 2012028435 A JP2012028435 A JP 2012028435A JP 2012139223 A5 JP2012139223 A5 JP 2012139223A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- residues
- binding protein
- human
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000023732 binding proteins Human genes 0.000 claims 64
- 108091008324 binding proteins Proteins 0.000 claims 64
- 229910052717 sulfur Inorganic materials 0.000 claims 25
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 claims 21
- 102000043959 human IL18 Human genes 0.000 claims 21
- 229910052727 yttrium Inorganic materials 0.000 claims 21
- 230000003472 neutralizing effect Effects 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 16
- 229910052757 nitrogen Inorganic materials 0.000 claims 14
- 229910052740 iodine Inorganic materials 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 229910052731 fluorine Inorganic materials 0.000 claims 11
- 208000019693 Lung disease Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 102000003810 Interleukin-18 Human genes 0.000 claims 9
- 108090000171 Interleukin-18 Proteins 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 229910052721 tungsten Inorganic materials 0.000 claims 8
- 229910052720 vanadium Inorganic materials 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 7
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229910052698 phosphorus Inorganic materials 0.000 claims 6
- 230000001154 acute effect Effects 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000001627 detrimental effect Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 229910052700 potassium Inorganic materials 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 231100000283 hepatitis Toxicity 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Chemical class 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000036487 Arthropathies Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- 208000003807 Graves Disease Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 2
- 101710205006 Interleukin-18-binding protein Proteins 0.000 claims 2
- 102100035017 Interleukin-18-binding protein Human genes 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 208000016604 Lyme disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000006045 Spondylarthropathies Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 210000004102 animal cell Anatomy 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000001913 cellulose Chemical class 0.000 claims 2
- 229920002678 cellulose Chemical class 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000001766 physiological effect Effects 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 241000271566 Aves Species 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 229920001651 Cyanoacrylate Polymers 0.000 claims 1
- 108050006400 Cyclin Proteins 0.000 claims 1
- 102000016736 Cyclin Human genes 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 108010002156 Depsipeptides Proteins 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 206010072268 Drug-induced liver injury Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000007984 Female Infertility Diseases 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018498 Goitre Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 206010021928 Infertility female Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 208000007466 Male Infertility Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000003351 Melanosis Diseases 0.000 claims 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims 1
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028665 Myxoedema Diseases 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010033165 Ovarian failure Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 206010057244 Post viral fatigue syndrome Diseases 0.000 claims 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010062164 Seronegative arthritis Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000026062 Tissue disease Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000018254 acute transverse myelitis Diseases 0.000 claims 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- LCWAOCHOPBSGMU-UHFFFAOYSA-J aluminum;magnesium;sodium;hydrogen carbonate;oxygen(2-);silicon;trihydroxide Chemical class [OH-].[OH-].[OH-].[O-2].[Na+].[Mg+2].[Al+3].[Si].OC([O-])=O LCWAOCHOPBSGMU-UHFFFAOYSA-J 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003092 anti-cytokine Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 231100000359 cholestasis Toxicity 0.000 claims 1
- 230000007870 cholestasis Effects 0.000 claims 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 229960005188 collagen Drugs 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008865 drug-induced hepatitis Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 229940014259 gelatin Drugs 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 claims 1
- 201000003872 goiter Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 102000057041 human TNF Human genes 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims 1
- 239000000832 lactitol Substances 0.000 claims 1
- 229960003451 lactitol Drugs 0.000 claims 1
- 235000010448 lactitol Nutrition 0.000 claims 1
- 201000002364 leukopenia Diseases 0.000 claims 1
- 231100001022 leukopenia Toxicity 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000003786 myxedema Diseases 0.000 claims 1
- ZTUGCJNAJJDKDC-UHFFFAOYSA-N n-(3-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCO ZTUGCJNAJJDKDC-UHFFFAOYSA-N 0.000 claims 1
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 201000004535 ovarian dysfunction Diseases 0.000 claims 1
- 231100000539 ovarian failure Toxicity 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000015385 phacoanaphylactic uveitis Diseases 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 229920000117 poly(dioxanone) Polymers 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 206010036601 premature menopause Diseases 0.000 claims 1
- 208000017942 premature ovarian failure 1 Diseases 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 230000002784 sclerotic effect Effects 0.000 claims 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 208000005057 thyrotoxicosis Diseases 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 230000003519 ventilatory effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/706,689 US20050100965A1 (en) | 2003-11-12 | 2003-11-12 | IL-18 binding proteins |
| US10/706,689 | 2003-11-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006539948A Division JP5054977B2 (ja) | 2003-11-12 | 2004-11-12 | Ｉｌ−１８結合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012139223A JP2012139223A (ja) | 2012-07-26 |
| JP2012139223A5 true JP2012139223A5 (enExample) | 2013-04-25 |
Family
ID=34552597
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006539948A Expired - Fee Related JP5054977B2 (ja) | 2003-11-12 | 2004-11-12 | Ｉｌ−１８結合タンパク質 |
| JP2010280298A Pending JP2011097946A (ja) | 2003-11-12 | 2010-12-16 | Ｉｌ−１８結合タンパク質 |
| JP2010280299A Pending JP2011097947A (ja) | 2003-11-12 | 2010-12-16 | Ｉｌ−１８結合タンパク質 |
| JP2012028435A Pending JP2012139223A (ja) | 2003-11-12 | 2012-02-13 | Ｉｌ−１８結合タンパク質 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006539948A Expired - Fee Related JP5054977B2 (ja) | 2003-11-12 | 2004-11-12 | Ｉｌ−１８結合タンパク質 |
| JP2010280298A Pending JP2011097946A (ja) | 2003-11-12 | 2010-12-16 | Ｉｌ−１８結合タンパク質 |
| JP2010280299A Pending JP2011097947A (ja) | 2003-11-12 | 2010-12-16 | Ｉｌ−１８結合タンパク質 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20050100965A1 (enExample) |
| EP (5) | EP2460829A3 (enExample) |
| JP (4) | JP5054977B2 (enExample) |
| KR (4) | KR20130006525A (enExample) |
| CN (4) | CN101948539B (enExample) |
| AT (1) | ATE555130T1 (enExample) |
| AU (1) | AU2004290073B2 (enExample) |
| BR (1) | BRPI0416255A (enExample) |
| CA (2) | CA2543920A1 (enExample) |
| CY (1) | CY1112893T1 (enExample) |
| DK (1) | DK1685152T3 (enExample) |
| ES (1) | ES2385484T3 (enExample) |
| IL (2) | IL175422A0 (enExample) |
| NZ (2) | NZ593068A (enExample) |
| PL (1) | PL1685152T3 (enExample) |
| PT (1) | PT1685152E (enExample) |
| SI (1) | SI1685152T1 (enExample) |
| WO (1) | WO2005047307A2 (enExample) |
| ZA (1) | ZA200603733B (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| TWI422387B (zh) | 2006-05-25 | 2014-01-11 | Glaxo Group Ltd | 免疫球蛋白 |
| EP2500413A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| EP2500416A1 (en) * | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| CN105111310B (zh) | 2006-11-21 | 2019-07-26 | 雅培制药有限公司 | 抗nogo-66受体(ngr)的中和单克隆抗体及其用途 |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| JP2011511777A (ja) * | 2008-01-30 | 2011-04-14 | アボット・ラボラトリーズ | 抗体断片を結晶化するための組成物及び方法 |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| JP2009284771A (ja) * | 2008-05-27 | 2009-12-10 | Takara Bio Inc | 抗体産生細胞の作製方法 |
| US20120308564A1 (en) | 2010-02-09 | 2012-12-06 | Andrew Ian Bayliffe | Treatment of a metabolic disorder |
| WO2012061448A1 (en) | 2010-11-04 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Anti-il-23 antibodies |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| US9255144B2 (en) | 2010-12-20 | 2016-02-09 | Medimmune Limited | Anti-IL-18 antibodies and their uses |
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| SG11201401360XA (en) | 2011-10-25 | 2014-05-29 | Onclave Therapeutics Ltd | Antibody formulations and methods |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US11078265B2 (en) * | 2012-05-03 | 2021-08-03 | Boehringer Ingelheim International Gmbh | Anti-IL-23 antibodies |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| BR112015004467A2 (pt) | 2012-09-02 | 2017-03-21 | Abbvie Inc | método para controlar a heterogeneidade de proteínas |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
| US9073875B2 (en) | 2012-11-20 | 2015-07-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
| US10570199B2 (en) | 2012-11-21 | 2020-02-25 | Km Biologics Co., Ltd. | Human antibody against IL-18 |
| KR101780575B1 (ko) | 2013-02-14 | 2017-09-21 | 건국대학교 산학협력단 | 신규한 인터루킨-33 수용체와 결합 단백질 조성물 및 그 용도 |
| CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| CN111423511B (zh) * | 2013-05-31 | 2024-02-23 | 索伦托药业有限公司 | 与pd-1结合的抗原结合蛋白 |
| AU2014317035B2 (en) * | 2013-09-05 | 2020-02-27 | Ab2 Bio Sa | IL-18 binding protein (IL-18BP) in inflammatory diseases |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| ES2909630T3 (es) * | 2014-06-04 | 2022-05-09 | Amgen Inc | Métodos de recolección en cultivos de células de mamífero |
| WO2016014775A1 (en) | 2014-07-24 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of il-23a related diseases |
| WO2016036918A1 (en) | 2014-09-03 | 2016-03-10 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| US10335449B2 (en) * | 2014-10-06 | 2019-07-02 | University Of Houston System | Rho associated kinase (ROCK) inhibitors and their use in treating disease |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| BR112017014684A2 (en) | 2015-02-04 | 2018-01-09 | Boehringer Ingelheim International Gmbh | methods of treatment of inflammatory diseases |
| SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| CN104725514A (zh) * | 2015-02-06 | 2015-06-24 | 中国药科大学 | 新型il23拮抗剂 |
| SG11201706879UA (en) * | 2015-03-05 | 2017-09-28 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases |
| KR101943989B1 (ko) | 2015-06-05 | 2019-01-30 | 삼성전자주식회사 | 데이터를 송수신하는 방법, 서버 및 단말기 |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| EP3419664A4 (en) * | 2016-02-25 | 2019-08-28 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | COMPOSITION AND METHOD FOR THE TREATMENT OF AMYOTROPHER LATERAL SCLEROSIS |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| WO2018038243A1 (ja) * | 2016-08-25 | 2018-03-01 | Ｊｃｒファーマ株式会社 | 抗体融合蛋白質の製造方法 |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| KR20200132938A (ko) | 2018-03-15 | 2020-11-25 | 추가이 세이야쿠 가부시키가이샤 | 지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법 |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| DE102018220631A1 (de) * | 2018-11-29 | 2020-06-04 | B. Braun Melsungen Ag | Wässrige Zusammensetzung, insbesondere zur Behandlung von Schleimhaut und/oder Wunden |
| EP3892300A4 (en) | 2018-12-03 | 2022-12-14 | Mabprotein Co.,Ltd. | ANTIBODIES RECOGNIZING A NEO-EPITOPE OF ACTIVATED INTERLEUKIN-18 PROTEINS AND ASSOCIATED APPLICATION |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| CN116323654A (zh) * | 2020-06-01 | 2023-06-23 | 阿瓦洛医疗公司 | 涉及il-18的抗体的方法及疗法 |
| CA3183994A1 (en) | 2020-06-24 | 2021-12-30 | Philip James Dolan Iii | Antibodies recognizing sortilin |
| JPWO2023286694A1 (enExample) | 2021-07-13 | 2023-01-19 | ||
| WO2023086336A2 (en) * | 2021-11-09 | 2023-05-19 | University Of Pittsburgh – Of The Commonwealth System Of Higher Education | Molecules that bind to prostate specific membrane antigen (psma) polypeptides |
| CA3235096A1 (en) | 2021-11-17 | 2023-05-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
| IL313812A (en) * | 2021-12-23 | 2024-08-01 | Prothena Biosciences Ltd | Antibodies that recognize SORTILIN |
| WO2023134767A1 (zh) * | 2022-01-14 | 2023-07-20 | 和径医药科技（上海）有限公司 | 一种靶向IL-18Rβ的抗体及其应用 |
| CN118852426A (zh) * | 2023-04-26 | 2024-10-29 | 北京惟奥生物科技有限公司 | 结合il-18受体的抗体、il-18受体激活剂及其应用 |
| WO2024243819A1 (zh) * | 2023-05-30 | 2024-12-05 | 上海洛启生物医药技术有限公司 | 抗白介素18受体的纳米抗体及其应用 |
| CN117986360B (zh) * | 2024-02-01 | 2024-08-27 | 生物岛实验室 | Il18蛋白的特异性抗体及其制备方法与应用 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US581438A (en) | 1897-04-27 | Buckle | ||
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH06506105A (ja) | 1990-08-29 | 1994-07-14 | ファーミング ビーブイ | 哺乳動物細胞における相同性組換え |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| DE69519454T2 (de) | 1994-07-14 | 2001-05-03 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama | Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| TW464656B (en) | 1994-11-15 | 2001-11-21 | Hayashibara Biochem Lab | Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| JPH11503914A (ja) | 1995-04-21 | 1999-04-06 | セル ジェネシス，インコーポレイテッド | 大ゲノムｄｎａ欠失の生成 |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
| CA2238885A1 (en) | 1995-12-29 | 1997-07-10 | Incyte Pharmaceuticals, Inc. | Nucleic acids encoding interferon gamma inducing factor-2 |
| DE69721548T2 (de) | 1996-02-09 | 2004-04-01 | Abbott Laboratories(Bermuda)Ltd. | HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| EP1669454A3 (en) | 1996-06-27 | 2009-04-01 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US7141393B2 (en) | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
| US6087116A (en) | 1997-03-12 | 2000-07-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18 (IL-18) receptor polypeptides and their uses |
| SK122199A3 (en) | 1997-03-18 | 2000-12-11 | Basf Ag | Methods and compositions for modulating responsiveness to corticosteroids |
| US6054487A (en) | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| CA2308438A1 (en) | 1997-11-03 | 1999-05-14 | The Wistar Institute Of Anatomy And Biology | Method and compositions for inhibiting angiogenesis and treating cancer |
| US6541606B2 (en) * | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
| NZ505499A (en) | 1998-01-23 | 2002-07-26 | Immunex Corp | Accessory protein-like DNA and polypeptides |
| PT1047781E (pt) | 1998-01-23 | 2004-11-30 | Immunex Corp | Receptores de il-18 |
| JP2002505097A (ja) | 1998-03-03 | 2002-02-19 | アブジェニックス インク． | 治療薬としてのｃｄ１４７結合分子 |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| CA2276216A1 (en) * | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
| JP2000236884A (ja) * | 1998-06-24 | 2000-09-05 | Hayashibara Biochem Lab Inc | ペプチド |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| EP1110969A4 (en) | 1998-09-01 | 2002-01-09 | Hayashibara Biochem Lab | INTERLEUKIN 18-BINDING PROTEINS |
| WO2000037504A2 (en) | 1998-12-23 | 2000-06-29 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| AR022952A1 (es) * | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
| AU3921600A (en) | 1999-03-25 | 2000-10-09 | Abbott Gmbh & Co. Kg | Human antibodies that bind human il-12 and methods for producing |
| US6440383B1 (en) | 1999-06-24 | 2002-08-27 | Altair Nanomaterials Inc. | Processing aqueous titanium chloride solutions to ultrafine titanium dioxide |
| CA2399148A1 (en) * | 2000-02-10 | 2001-08-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
| AU2001259432B2 (en) | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| KR100787073B1 (ko) | 2000-06-28 | 2007-12-21 | 글리코파이, 인크. | 변형된 당단백질의 제조방법 |
| KR20030074693A (ko) | 2000-12-28 | 2003-09-19 | 알투스 바이올로직스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| ES2405551T3 (es) | 2001-10-01 | 2013-05-31 | Dyax Corporation | Vectores de presentación eucariotas multicatenarios y usos de los mismos |
| US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
-
2003
- 2003-11-12 US US10/706,689 patent/US20050100965A1/en not_active Abandoned
-
2004
- 2004-11-12 BR BRPI0416255-2A patent/BRPI0416255A/pt not_active IP Right Cessation
- 2004-11-12 CN CN2010102739861A patent/CN101948539B/zh not_active Expired - Fee Related
- 2004-11-12 EP EP11173615A patent/EP2460829A3/en not_active Withdrawn
- 2004-11-12 ES ES04817825T patent/ES2385484T3/es not_active Expired - Lifetime
- 2004-11-12 KR KR1020127031335A patent/KR20130006525A/ko not_active Ceased
- 2004-11-12 SI SI200431865T patent/SI1685152T1/sl unknown
- 2004-11-12 CN CN2012101293119A patent/CN102659944A/zh active Pending
- 2004-11-12 AT AT04817825T patent/ATE555130T1/de active
- 2004-11-12 EP EP04817825A patent/EP1685152B1/en not_active Expired - Lifetime
- 2004-11-12 KR KR1020127001647A patent/KR101282320B1/ko not_active Expired - Fee Related
- 2004-11-12 AU AU2004290073A patent/AU2004290073B2/en not_active Ceased
- 2004-11-12 KR KR1020067009221A patent/KR20060123148A/ko not_active Ceased
- 2004-11-12 KR KR1020127028781A patent/KR20120136416A/ko not_active Ceased
- 2004-11-12 CA CA002543920A patent/CA2543920A1/en not_active Abandoned
- 2004-11-12 NZ NZ593068A patent/NZ593068A/xx not_active IP Right Cessation
- 2004-11-12 EP EP11173650A patent/EP2395020A3/en not_active Withdrawn
- 2004-11-12 JP JP2006539948A patent/JP5054977B2/ja not_active Expired - Fee Related
- 2004-11-12 EP EP11173595A patent/EP2385070A1/en not_active Withdrawn
- 2004-11-12 PL PL04817825T patent/PL1685152T3/pl unknown
- 2004-11-12 WO PCT/US2004/037971 patent/WO2005047307A2/en not_active Ceased
- 2004-11-12 CN CN201010274020XA patent/CN101979412A/zh active Pending
- 2004-11-12 NZ NZ582097A patent/NZ582097A/en not_active IP Right Cessation
- 2004-11-12 PT PT04817825T patent/PT1685152E/pt unknown
- 2004-11-12 CA CA2805859A patent/CA2805859A1/en not_active Abandoned
- 2004-11-12 DK DK04817825.5T patent/DK1685152T3/da active
- 2004-11-12 EP EP11173631A patent/EP2460830A3/en not_active Withdrawn
- 2004-11-12 CN CN2004800399482A patent/CN1902229B/zh not_active Expired - Fee Related
-
2006
- 2006-05-04 IL IL175422A patent/IL175422A0/en unknown
- 2006-05-10 ZA ZA200603733A patent/ZA200603733B/en unknown
-
2010
- 2010-07-13 IL IL206979A patent/IL206979A0/en unknown
- 2010-12-16 JP JP2010280298A patent/JP2011097946A/ja active Pending
- 2010-12-16 JP JP2010280299A patent/JP2011097947A/ja active Pending
-
2012
- 2012-02-13 JP JP2012028435A patent/JP2012139223A/ja active Pending
- 2012-07-05 CY CY20121100602T patent/CY1112893T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012139223A5 (enExample) | ||
| JP2011097946A5 (enExample) | ||
| RU2461571C2 (ru) | Белки, связывающие il-12/p40 | |
| CN102958537B (zh) | TNF-α结合蛋白 | |
| US8624002B2 (en) | Prostaglandin E2 binding proteins and uses thereof | |
| JP5536666B2 (ja) | 痛風の治療のための方法 | |
| RU2012112067A (ru) | Терапевтические dll4-связующие белки | |
| US9725515B2 (en) | Prolactin receptor binding proteins and uses thereof | |
| CN103946240B (zh) | 对人ox40具有特异性的抗体分子 | |
| TWI631957B (zh) | 抗－ｉｌ－２３抗體 | |
| JP2011527579A5 (enExample) | ||
| JP2010502224A5 (enExample) | ||
| RU2011140335A (ru) | Связывающие il-17 белки | |
| JP2012519708A5 (enExample) | ||
| TW201124427A (en) | IL-1 binding proteins | |
| KR20190107184A (ko) | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| JP2012139223A (ja) | Ｉｌ−１８結合タンパク質 | |
| JP2016522793A (ja) | ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質 | |
| JP6154847B2 (ja) | 疾患治療組成物 | |
| EP3113796A1 (en) | Method of using antibody polypeptides that antagonize cd40 to treat ibd | |
| WO2013009521A9 (en) | Methods and compositions for treating asthma using anti-il-13 antibodies | |
| CN104144946A (zh) | 治疗痤疮的方法 | |
| CN116059350A (zh) | 使用抗-il-17a/f抗体的治疗方法 | |
| AU2015200579A1 (en) | TNF-alpha binding proteins | |
| NZ614207B2 (en) | Treatment of osteoarthritis and pain |